Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2022-11-30 Purchase | 2022-12-01 4:35 pm | Theseus Pharmaceuticals Inc. | THRX | Dahms Bradford D. Chief Financial Officer | 1,502 | $6.657 | $10,000 | 6,142 (Direct) | View |
| 2021-12-21 Purchase | 2021-12-22 6:21 pm | Theseus Pharmaceuticals Inc. | THRX | Dahms Bradford D. Chief Financial Officer | 1,970 | $10.15 | $20,000 | 1,970 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-02-14 Disposition | 2024-02-14 4:00 pm | N/A N/A | Theseus Pharmaceuticals Inc. | THRX | Dahms Bradford D. President and CFO | 349,614 | $0 | 0 (Direct) | View |
| 2024-02-14 Equity Swap | 2024-02-14 4:00 pm | N/A N/A | Theseus Pharmaceuticals Inc. | THRX | Dahms Bradford D. President and CFO | 8,150 | $0 | 0 (Direct) | View |
| 2023-03-01 Option Award | 2023-03-02 07:00 am | N/A N/A | Theseus Pharmaceuticals Inc. | THRX | Dahms Bradford D. Chief Financial Officer | 17,500 | $0 | 17,500 (Direct) | View |
| 2023-02-17 Option Award | 2023-02-21 07:01 am | N/A 2033-02-17 | Theseus Pharmaceuticals Inc. | THRX | Dahms Bradford D. Chief Financial Officer | 105,000 | $0 | 105,000 (Direct) | View |
| 2022-02-18 Option Award | 2022-02-23 8:00 pm | N/A 2032-02-17 | Theseus Pharmaceuticals Inc. | THRX | Dahms Bradford D. Chief Financial Officer | 150,000 | $0 | 150,000 (Direct) | View |
Ownership | 2021-10-06 7:00 pm | N/A 2031-05-26 | Theseus Pharmaceuticals Inc. | THRX | Dahms Bradford D. Chief Financial Officer | 0 | $0 | 355,999 (Direct) | View |
| 2021-01-04 Option Award | 2021-01-06 4:49 pm | N/A 2031-01-03 | SELECTA BIOSCIENCES INC | SELB | Dahms Bradford D. Chief Financial Officer | 268,000 | $0 | 268,000 (Direct) | View |
| 2020-07-01 Option Award | 2020-07-06 4:11 pm | N/A 2030-06-30 | SELECTA BIOSCIENCES INC | SELB | Dahms Bradford D. Chief Financial Officer | 40,000 | $0 | 40,000 (Direct) | View |
| 2020-01-02 Option Award | 2020-01-06 8:07 pm | N/A 2030-01-01 | SELECTA BIOSCIENCES INC | SELB | Dahms Bradford D. Chief Financial Officer | 140,000 | $0 | 140,000 (Direct) | View |
| 2019-09-03 Option Award | 2019-09-05 5:29 pm | N/A 2029-09-02 | SELECTA BIOSCIENCES INC | SELB | Dahms Bradford D. Chief Financial Officer | 400,000 | $0 | 400,000 (Direct) | View |